J Clin Oncol: Over 10-year OS results from the randomized FinXX study suggest that adding capecitabine to adjuvant chemotherapy improves outcomes in patients with early breast cancer

FinXX is a randomized, open-label, multicenter trial evaluating capecitabine added to an adjuvant chemotherapy regimen containing a taxane and an anthracycline in early-stage breast cancer
.

Recently, the Journal of Clinical Oncology published its OS results with more than 10 years of follow-up

FinXX is a randomized, open-label, multicenter trial evaluating capecitabine added to an adjuvant chemotherapy regimen containing a taxane and an anthracycline in early-stage breast cancer

Between January 27, 2004, and May 29, 2007, 1500 patients with axillary node-positive or high-risk node-negative early-stage breast cancer were enrolled
.

Patients were randomly assigned to: TX-CEX (3 cycles of docetaxel + capecitabine followed by 3 cycles of cyclophosphamide + doxorubicin + capecitabine; n=753) and T-CEF (3 cycles of docetaxel followed by 3 cycles of cyclophosphamide + doxorubicin + fluorouracil; n = 747 patients)

Between January 27, 2004, and May 29, 2007, 1500 patients with axillary node-positive or high-risk node-negative early-stage breast cancer were enrolled

Data collection locked on December 31, 2020

During follow-up, 375 (25.

Differences in OS between the two groups

Differences in OS between the two groups

The 5-, 10-, and 15-year OS rates in the TX-CEX and T-CEF groups were 92.
7% and 90.
2%, 84.
3% and 82.
3%, and 77.
6% and 73.
3%, respectively
.

The 5-, 10-, and 15-year OS rates in the TX-CEX and T-CEF groups were 92.
7% and 90.
2%, 84.
3% and 82.
3%, and 77.
6% and 73.
3%, respectively
.

The 5-, 10-, and 15-year OS rates in the TX-CEX and T-CEF groups were 92.

                 OS subgroup analysis

OS subgroup analysis

In the TNBC subgroup, the 5-, 10-, and 15-year survival rates in the TX-CEX group were 88.
2%, 81.
7%, and 74.
5%, respectively, while those in the T-CEF group were 75.
2%, 69.
7%, and 64.
2%, respectively ( HR 0.
59; 95% CI, 0.
36 to 0.
97; log-rank test P=0.
051; Gehan-Breslow-Wilcoxon test P=0.
033)
.

In the TNBC subgroup, the 5-, 10-, and 15-year survival rates in the TX-CEX group were 88.
2%, 81.
7%, and 74.
5%, respectively, while those in the T-CEF group were 75.
2%, 69.
7%, and 64.
2%, respectively ( HR 0.
59; 95% CI, 0.
36 to 0.
97; log-rank test P=0.
051; Gehan-Breslow-Wilcoxon test P=0.
033)
.

In the TNBC subgroup, the 5-, 10-, and 15-year survival rates in the TX-CEX group were 88.

                OS subgroup analysis

  OS subgroup analysis

In conclusion, the FinXX study showed that the addition of capecitabine to adjuvant chemotherapy could improve the prognosis of patients with early breast cancer
.

In conclusion, the FinXX study showed that the addition of capecitabine to adjuvant chemotherapy could improve the prognosis of patients with early breast cancer
.

The FinXX study showed that the addition of capecitabine to adjuvant chemotherapy improved outcomes in patients with early breast cancer

Original source:

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, Tanner M, Ahlgren J, Auvinen P, Lahdenperä O, Villman K, Nyandoto P, Nilsson G, Poikonen-Saksela P, Kataja V, Bono P, Junnila J, Lindman H.

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, Tanner M, Ahlgren J, Auvinen P, Lahdenperä O, Villman K, Nyandoto P, Nilsson G, Poikonen-Saksela P, Kataja V, Bono P, Junnila J, Lindman H.
Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
J Clin Oncol.
2022 Jan 12:JCO2102054.
doi: 10.
1200/JCO.
21.
02054.
Epub ahead of print.
PMID: 35020465.
Leave a comment here